Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/Valsartan vs Enalapril for Erectile Function in HFrEF
NCT03917459Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacubitril + valsartan in erectile dysfunction (ED), heart failure with reduced ejection fraction (HFrEF), sponsored by Novartis. Started Apr 2019; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
erectile dysfunction (ED)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03917459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917459.